{"schema_version":"secwatch.filing_event.v1","accession":"0000012208-24-000036","form_type":"8-K","ticker":"BIO","cik":"0000012208","company_name":"BIO-RAD LABORATORIES, INC.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.596936+00:00","generated_at":"2026-06-02T16:26:44.091182+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Bio-Rad Q1 net sales down 9.8% to $610.8M; Life Science segment falls 25.3% YoY","bullets":["Net sales $610.8M, down 9.8% YoY (currency-neutral -9.6%); operating income $44.7M vs $61.9M.","Life Science segment $241.7M (-25.3% YoY) due to biotech/biopharma weakness; Clinical Diagnostics $368.6M (+4.7%) grew.","Net income $383.9M ($13.45 diluted) vs $69.0M ($2.32), largely from fair value changes of Sartorius AG equity holdings.","CEO Norman Schwartz: Q1 in line with expectations; cautiously optimistic for gradual biopharma recovery in H2 2024.","Effective tax rate 21.8% vs 18.7% a year ago, affected by equity securities treatment."],"urls":{"canonical":"https://secwatch.observer/filing/0000012208-24-000036","json":"https://secwatch.observer/filing/0000012208-24-000036.json","markdown":"https://secwatch.observer/filing/0000012208-24-000036.md","text":"https://secwatch.observer/filing/0000012208-24-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/12208/000001220824000036/0000012208-24-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/12208/000001220824000036/bio-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T16:26:44.091182+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dd44ada40f549ad68fb54df528e39b8a3efe5e4d","claim":"BIO-RAD LABORATORIES, INC. reported the first quarter ended March 31, 2024 results: revenue $610.8 million, net income $383.9 million, EPS $13.45 per share, on a diluted basis.","evidence_excerpt":"Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the first quarter ended March 31, 2024. First-quarter 2024 total net sales were $610.8 million, a decrease of 9.8 percent compared to $676.8 million reported for the first quarter of 2023. On a currency-neutral basis, quarterly sales decreased 9.6 percent compared to the same period in 2023. Life Science segment net sales for the first quarter were $241.7 million, a decrease of 25.3 percent compared to the same period in 2023. On a currency-neutral basis, Life Science segment sales decreased by 25.2 percent compared to the same quarter in 2023. The currency-neutral year-over-year sales decrease was broad-based and was primarily driven by ongoing weakness in the biotech and biopharma end-markets and the economic environment in China. Clinical Diagnostics segment net sales for the first quarter were $368.6 million, an increase","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/12208/000001220824000036/0000012208-24-000036-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$610.8 million"},{"label":"Net income","value":"$383.9 million"},{"label":"EPS","value":"$13.45 per share, on a diluted basis"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}